Cabot Medical
This article was originally published in The Gray Sheet
Executive Summary
Receives clearance from FDA to market the Seitzinger Tripolar cutting forceps, the firm announces Aug. 9. Designed "to replace more expensive stapling devices" in procedures such as hysterectomies, gall bladder removal, appendectomies and other gynecological and general surgical procedures, the device "enables the surgeon to cauterize tissue to reduce or eliminate bleeding, while activating a cutting knife allowing the tissue to be transected in a one-handed operation." The firm maintains that "in addition to the savings from not using any staples, the operating time can be reduced by as much as one third" with use of the device
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.